43 results about "Urea derivatives" patented technology

The invention relates to the technical field of medicines, in particular to fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutically acceptable salts, stereoisomers, pharmaceutical compositions and application thereof. The structure of the fused tricyclic substituted isoxazolidinyl urea derivative is as shown in a formula (I). The fused tricyclic substituted isoxazolidinyl urea derivative disclosed by the invention has obvious TrkA kinase and cell inhibition activity and selective inhibition activity.

The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, 25% to 40% by weight of urea and / or urea derivatives relative to the total weight of the composition; at least one saccharide-free non-emulsifying hydrophilic gelling polymer; at least one scleroglucan gum; the composition containing less than 2% by weight of surfactant relative to the total weight of the composition, preferably less than 1%, even more preferably less than 0.5% or no surfactant at all. It also relates to the use of a cosmetic composition of this kind for skin care, in particular for the skin of the face or body, as well as to a cosmetic skin care method, in particular for the skin of the face or body, involving the application of a cosmetic composition of this kind.

Bisorthohydroxy aromatic urones and their use as curatives and cure accelerators in resin systems particularly epoxy resin systems provide formulations with good outlife, low curing temperatures and desirable glass transition temperatures after curing, they are particularly useful in prepregs used in the production of components for the aerospace and wind turbine industries.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

This invention relates to a sprayable hair care product in the form of an oil-in-water emulsion, having a pH value of 3.0 to 7.0 at 20°C, comprising at least one water-insoluble oil component (A), at least one nonionic emulsifier (B), at least one nonionic co-emulsifier (C), water, and a buffer system for stabilizing the pH value, wherein the water content is equal to 60 to 90% by weight, component (A) is provided in an amount of 1.5 to 20% by weight, and components (B) and (C) are provided in a total amount of 1 to 12% by weight. The invention is characterized in that adenosine is provided in an amount of 0.01 to 3% by weight, and urea and / or urea derivatives are provided in a total amount of 1.0 to 25% by weight. This invention also relates to a method for preparing a sprayable aqueous formulation of adenosine, wherein an aqueous solution of adenosine is mixed with a finely dispersed emulsion of an oil component (A) such that the formulation contains 1.5 to 20% by weight of the emulsified oil component (A), wherein the average droplet diameter of the oil component (A) (measured using a device based on the principle of quasi-elastic light scattering (Zetasizer Nano ZS, 25°C, square polystyrene cuvette, 12 mm side length (model DTS0012), dilution: 0.025% w / w in water)) is less than 1 μm. During or after preparation and before mixing with the adenosine solution, the emulsion is brought to a phase transition temperature, and urea and / or urea derivatives are added to the resulting mixture at room temperature. This invention also relates to the use of a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives with an ethanol content of less than 18% by weight for cosmetic treatment of the skin, particularly the scalp.

The present invention pertains to a process for preparing an isocyanate-containing compound comprising the step of reacting a compound of formula (1) (1) with oxalyl chloride.

The purpose of the present invention is to provide a method for simultaneously performing concentration and deproteinization of natural rubber latex.　The present invention relates to: a method for concentrating natural rubber latex, the method being characterized by adding a surfactant, urea or a urea derivative, a compound that is selected from the group consisting of hydroxide salts, ammonia and salts thereof, and optionally a polar organic solvent to natural rubber latex, introducing a gas containing at least 0.1-100% by volume of carbon dioxide into the natural rubber latex, leaving the natural rubber latex to stand still so as to separate the natural rubber latex into a cream phase and a serum phase, and recovering the cream phase; and a method for producing a concentrated natural rubber.

Bis-orthohydroxy aromatic urones and their use as curing agents and cure accelerators in resin systems, particularly epoxy resin systems, provide formulations with good longevity, low cure temperatures, and desirable glass transition temperatures after cure, and are particularly useful in prepregs used in the manufacture of parts for the aerospace and wind turbine industries.

Described herein are novel piperidine urea derivative compounds and pharmaceutical compositions thereof for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolases.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

To suppress polyene formation in a polarizer made of a polyvinyl alcohol resin film.SOLUTION: A polarizing plate 100 includes a polarizer 101 in which a dichroic dye is adsorbed and aligned on a polyvinyl alcohol-based resin film, and a protective film 103 laminated on at least one surface of the polarizer 101 via an adhesive layer 102. The adhesive layer 102 contains a urea compound. The polarizer 101 contains a radical scavenger. The urea compound is at least one selected from the group consisting of urea, urea derivatives, thiourea, and thiourea derivatives. The radical scavenger is a hindered amine compound.SELECTED DRAWING: Figure 1

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Described herein are novel piperidine urea derived compounds and pharmaceutical compositions thereof for the treatment of conditions and diseases mediated by soluble epoxide hydrolases.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.

A thermally expandable composition includes at least one epoxy-functional polymer, at least one endothermic chemical blowing agent, and at least one curative selected from the group made of a urea, urea derivatives, guanidine derivatives, amidine derivatives, and imidazoles. Further, a baffle and / or a reinforcement element for hollow structures includes the thermally expandable composition, a process manufactures the baffle and / or the reinforcement element, the baffle and / or the reinforcement element is used for sealing, baffling, or reinforcing of a cavity or a hollow structure, and a method seals, baffles and / or reinforces a cavity or hollow structure.

Described herein are novel piperidine urea derivative compounds and pharmaceutical compositions thereof for the treatment of cancer as monotherapy or in combination with chemotherapeutic agents and / or checkpoint inhibitors.

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None

The present invention relates to a reducing agent, comprising: a sulfinate of formula I, wherein R1 is H or C1-C6 hydrocarbyl, R2 is C1-C6 hydrocarbyl or M', and M and M' are each independently at least one monovalent cation or a combination with at least one multivalent cation; and optionally, urea or a urea derivative. The reducing agent contains essentially no sulfonic acid or sulfonate. In addition, the present invention relates to a preparation method for the reducing agent. The reducing agent can effectively improve the properties of a polymerization product when used for emulsion polymerization and preparation of a water-soluble polymer.

The invention discloses an alkyne aromatic heterocyclic urea derivative, and particularly relates to a free alkali, an isomer or a pharmaceutically acceptable salt of the derivative and other substance forms. Furthermore, the invention also discloses a preparation method and pharmaceutical application of the alkyne aromatic heterocyclic urea derivative, and the alkyne aromatic heterocyclic urea derivative can be used as an RIPK1 inhibitor for treating diseases related to abnormal expression of a mediated RIPK1 signal channel, including but not limited to tumors, inflammatory diseases or diseases accompanied by inflammatory reactions, autoimmune diseases, neurodegenerative diseases and the like, and has a broad application prospect. The clinical development value is great.

This invention relates to a sprayable hair care product in the form of an oil-in-water emulsion, comprising at least one water-insoluble oil component (A), at least one nonionic emulsifier (B), at least one nonionic co-emulsifier (C), and water, wherein the water content is 60-90% by weight, the content of component (A) is 1.5-20% by weight, and the total content of components (B) and (C) is 1-12% by weight. A key feature of this invention is that the adenosine content is 0.01-3% by weight, and the total content of urea and / or urea derivatives is 1.0-25% by weight. This invention also relates to a method for preparing a sprayable aqueous adenosine formulation, wherein an aqueous adenosine solution is mixed with a finely dispersed emulsion of an oil component (A), the average droplet diameter of which is less than 1 μm (measured using a device based on the principle of semi-elastic light scattering (Zetasizer Nano ZS, 25°C, square polystyrene cuvette, 12 mm side length (model DTS0012), dilution: 0.025% w / w in water)), and the amount of which is such that the formulation contains 1.5 to 20% by weight of the emulsified oil component (A). During or after preparation and before mixing with the adenosine solution, the emulsion is heated to the phase inversion temperature, and urea and / or urea derivatives are added to the resulting mixture at room temperature. This invention also relates to a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives and having an ethanol content of less than 18% by weight for use in cosmetic treatments of the skin, particularly the scalp.

The invention provides a synthesis method of a 3-piperidine-phenyl urea derivative. Specifically, the invention provides a preparation method of a compound as shown in a formula I. The preparation method comprises the following steps.

The present application relates to aqueous sprayable hair supplements comprising urea and / or urea derivatives in a total amount of 1.0 to 20 wt.-%, and adenosine in an amount of 0.05 to 3 wt.-%, wherein the hair supplements comprise less than 18 wt.-%, preferably at most 10 wt.-%, in particular at most 5 wt.-%, of ethanol; and the use of a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives with an ethanol content of less than 18 wt.-% for cosmetic treatment of the skin, in particular the scalp.

This disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing sickle cell disease or conditions associated thereto. In certain embodiments, the compounds are 1-(thiazol-2-yl)urea derivatives. In certain embodiments, the compounds are 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivatives. In certain embodiments, the compounds are 1-phenyl-1H-pyrrole-2,5-dione derivatives. In certain embodiments, this disclosure relates to methods of treating or preventing sickle cell disease or condition associated thereto comprising administering an effective amount of a 1-(thiazol-2-yl)urea derivative, or 1-phenyl-1H-pyrrole-2,5-dione derivative, or a 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivative as disclosed herein to a subject in need thereof.

The invention relates to the technical field of composite formaldehyde reducing agents, in particular to a composite formaldehyde reducing agent in the field of wood composite materials, and the composite formaldehyde reducing agent comprises (i) 50-55% of a physical formaldehyde reducing component selected from nano montmorillonite, activated carbon, nano silicon dioxide and a combination thereof, (ii) 27-35% of a chemical formaldehyde reducing component selected from nano montmorillonite, activated carbon, nano silicon dioxide and a combination thereof, and (iii) 0.5-5% of a water reducing agent. The chemical formaldehyde-reducing component is selected from amine compounds, amino compounds, urea derivatives, urotropine (hexamethylenetetramine), polyhydroxy alcohol and combinations thereof, and (iii) 9.6-15% of other additive components, and the adding percentage of each component is the mass percentage based on the total mass of the composite formaldehyde-reducing agent. The formaldehyde reduction efficiency can be improved, the formaldehyde reduction validity period is prolonged, the formaldehyde reduction validity period covers a short period, a middle period and a long period, and the formaldehyde reduction effect in each stage is continuous and stable.

The present invention relates to amine resole phenolic resins stabilized with a solubilizing agent selected from certain urea derivatives, sizing compositions made from said resins, a method for manufacturing fiber-based insulation products, in particular mineral wool-based insulation products, using said sizing compositions, and a method for manufacturing fiber-based insulation products, in particular mineral wool-based insulation products, in particular mineral wool-based insulation products, in particular mineral wool-based insulation products, in particular mineral wool-based insulation products, in particular mineral wool-based insulation products, in particular mineral wool-based insulation products. And a thermally and / or acoustically insulating product obtained by said manufacturing method.

COMPOSITION COMPRISING UREA OR ONE OF ITS DERIVATIVES, A POLYCARBOXYLIC ACID AND A MULTIVALENT CATION SALT The invention relates to a cosmetic composition comprising: a) one or more compounds chosen from urea and / or urea derivatives, b) one or more carboxylic acids and / or their salts chosen from monohydroxylated polycarboxylic acids and non-hydroxylated polycarboxylic acids having at least a pKa of less than or equal to 4.25, c) one or more inorganic salts of multivalent cations. It also relates to the use of this composition for smoothing keratin fibers. Finally, it relates to a treatment method, in particular for smoothing and relaxing keratin fibers.

The present disclosure relates to compounds of Formula (I):and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.